Mineral metabolism in heart disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 4, 2015, Pages 310-316

  Heine, Gunnar H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiovascular disease; Fibroblast growth factor 23; Hyperphosphatemia; Hypovitaminosis D

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; FIBROBLAST GROWTH FACTOR; MINERAL;

ACUTE HEART FAILURE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; HEART DISEASE; HEART MUSCLE; HUMAN; HYPERPHOSPHATEMIA; LONGITUDINAL STUDY; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR TISSUE; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY; ANIMAL; CHRONIC KIDNEY FAILURE; COMPLICATION; HEART DISEASES; METABOLIC DISORDER; METABOLISM;

ANIMALS; FIBROBLAST GROWTH FACTORS; HEART DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC DISEASES; MINERALS; PARATHYROID HORMONE;

EID: 84942776458     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000129     Document Type: Review

References (37)

1. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 2013;24:179-189.
2. Di Marco GS, Konig M, Stock C, et al. High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int 2013;83:213-222.
3. Neves KR, Graciolli FG, Dos Reis LM, et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-2244.
4. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633.
5. Ellam TJ, Chico TJ. Phosphate: the new cholesterol? The role of the phosphate axis in nonuremic vascular disease. Atherosclerosis 2012;220:310-318.
6. Palomino HL, Rifkin DE, Anderson C, et al. 24-h urine phosphorus excretion and mortality and cardiovascular events. Clin J Am Soc Nephrol 2013;8:1202-1210.
7. Wannamethee SG, Sattar N, Papcosta O, et al. Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. Arterioscler Thromb Vasc Biol 2013;33:1070-1076.
8. Chang AR, Grams ME. Serum phosphorus and mortality in the Third National & Health and Nutrition Examination Survey (NHANES III): effect modification by fasting. Am J Kidney Dis 2014;64:567-573. A large-scale epidemiological study on the prognostic role of phosphate in the general population, highlighting the importance of adequate sampling conditions.
9. Chang AR, Lazo M, Appel LJ, et al. High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr 2014;99:320-327.
10. Heine GH, Nangaku M, Fliser D. Calcium and phosphate impact cardiovascular risk. Eur Heart J 2013;34:1112-1121.
11. Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident & coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014;3:e000936. The largest prospective epidemiological study so far on FGF-23 and cardiovascular outcome.
12. Kestenbaum B, Sachs MC, Hoofnagle AN, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2014;7:409-417.
13. Brandenburg VM, Kleber ME, Vervloet MG, et al. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 2014;237:53-59.
14. Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014;25:349-360.
15. Seiler S, Rogacev KS, Roth HJ, et al. Associations of FGF-23and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin JAm Soc Nephrol 2014;9:1049-1058.
16. Lindberg K, Olauson H, Amin R, et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013;8:e60658.
17. Scialla JJ, Lau WL, Reilly MP, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013;83:1159-1168.
18. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
19. Di Marco GS, Reuter S, Kentrup D, et al. Treatment of established left & ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 2014;29:2028-2035. Experimental data confirming a seminal paper from the same group on a direct role of FGF-23 in left ventricular hypertrophy.
20. Amaral AP, Grabner A, Singh S, et al. FGF23 targets the heart by activating FGFR4 [Abstract]. J Am Soc Nephrol 2014;25:26A.
21. Grabner A, Amaral AP, Singh S, et al. Pharmacologic FGFR4 blockade attenuates LVH in a rodent model of CKD [Abstract]. J Am Soc Nephrol 2014;25:26A.
22. Agarwal I, Ide N, Ix JH, et al. Fibroblast growth factor-23 and cardiac structure & and function. J Am Heart Assoc 2014;3:e000584. One of the largest epidemiological studies on the prognostic implications of FGF-23 in individuals without advanced CKD.
23. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:2543-2553.
24. Seiler S, Cremers B, Rebling NM, et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011;32:2688-2696.
25. Mathew JS, Sachs MC, Katz R, et al. Fibroblast growth factor-23 and incident & atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014;130:298-307. The first longitudinal study which observes an association of FGF-23 with specific stroke subtypes.
26. Panwar B, Jenny NS, Howard VJ, et al. Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke 2015;46:322-328.
27. Poelzl G, Trenkler C, Kliebhan J, et al. FGF23 is associated with disease severity & and prognosis in chronic heart failure. Eur J Clin Invest 2014;44:1150-1158. Epidemiological study which confirms a prognostic role of elevated FGF-23 in chronic heart failure.
28. Gruson D, Ahn SA, Rousseau MF. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure. Peptides 2015;64C: 24-28.
29. Fuernau G, Poss J, Denks D, et al. Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the intra-aortic balloon pump in cardiogenic shock II (IABP-SHOCK II) trial. Crit Care 2014;18:713.
30. Poss J, Mahfoud F, Seiler S, et al. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2013;2:211-218.
31. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 2010;3:195-201.
32. Boxer RS, Kenny AM, Schmotzer BJ, et al. A randomized controlled trial of high dose vitamin D3 in patients with heart failure. JACC Heart Fail 2013;1:84-90.
33. Scragg R, Slow S, Stewart AW, et al. Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: a randomized controlled trial. Hypertension 2014;64:725-730.
34. Arora P, Song Y, Dusek J, et al. Vitamin D therapy in individuals with & prehypertension or hypertension: the DAYLIGHT trial. Circulation 2015;131:254-262. Randomised controlled trial with fails to detect an antihypertensive effect of vitamin D supplementation.
35. Witham MD, Ireland S, Houston JG, et al. Vitamin D therapy to reduce blood & pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension 2014;63:706-712. One of the few intervention trials in mineral metabolism with a pre-defined cardiovascular outcome.
36. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for & prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470. State-of-the-art metaanalysis which does not find significant benefit of vitamin D supplementation on cardiovascular survival.
37. Afzal S, Brondum-Jacobsen P, Bojesen SE, Nordestgaard BG. Genetically & low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ 2014;349:g6330. A Mendelian randomisation analysis which suggests against an independent role of 25-OH vitamin D in cardiovascular outcome.